<DOC>
	<DOCNO>NCT00788294</DOCNO>
	<brief_summary>The hypothesis study subcutaneous administration tanezumab result low drug exposure compare intravenous administration tanezumab .</brief_summary>
	<brief_title>Measure Exposure Of Tanezumab In Healthy Volunteers When Administering The Drug Subcutaneously</brief_title>
	<detailed_description />
	<criteria>Generally healthy BMI 1830 kg/m2 50 kg bodyweight . Pregnant exposure biologic type drug within last 3 month history allergic anaphylactic reaction biologic drug use tobacco nicotine containing product 5 cigarette per day excessive alcohol use .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Pharmacokinetics tanezumab subcutaneous bioavailability intravenous Japanese subject</keyword>
</DOC>